EUVIMEDEUVIMED entdecken
Crossref

Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

Satenik Harutyunova, Nicola Benjamin, Christina Eichstaedt, Alberto M Marra, Panagiota Xanthouli, Christian Nagel, Ekkehard Grünig, Benjamin Egenlauf

Respiration · 2023

DOI: 10.1159/000531169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiration, 2023. Verfasst von Satenik Harutyunova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany, satenik.harutyunova@med.uni-heidelberg.de. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines recommend treatment with parenteral prostacyclin analogs in patients with severe pulmonary arterial hypertension (PAH), who have insufficient response to treatment. Real-life data are sought to help physicians in treatment decisions and clinical care of patients.

Objective

This study analyzed safety, clinical effects, and long-term outcomes of subcutaneous (sc) and/or intravenous (iv) treprostinil via different pump systems in consecutive patients with PAH.

Methods

Thirty-seven patients with severe progressive PAH despite dual combination therapy (20 female, mean age: 52.3 ± 15 years, mean pulmonary vascular resistance: 12.1 ± 5.1 WU) were initiated with add-on treprostinil sc and were routinely clinically assessed. Changes in clinical parameters, adverse events, and outcome were analyzed retrospectively.

Results

In 24 of 37 patients, treprostinil administration was continued iv via implantation of LENUS Pro® pump after 3 ± 1.3 months, 6 patients continued with sc therapy, and 7 discontinued treatment. After 3, 6, 9, and 12 months of treprostinil treatment, patients showed a significant improvement in mean 6-min walk distance and tricuspid annular plane systolic excursion compared to baseline. In 8 of the 24 patients, iv pumps required surgical revision. During a mean follow-up of 2.82 ± 1.95 years, 12 patients died, four received lung transplantation. Transplant-free survival after 1, 2, and 3 years was 85.7%, 69.2%, and 65.3%, respectively. Conclusion: sc treprostinil as add-on to double combination treatment significantly improved exercise capacity and right heart function. In most patients, treprostinil could be continued via more tolerable iv administration approach (LENUS Pro® pump), showing reasonable overall survival with respect to the severity of PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHypertension, PulmonaryHumansFemaleAdultMiddle AgedAgedAntihypertensive AgentsRetrospective StudiesTreatment OutcomeEpoprostenolFamilial Primary Pulmonary Hypertension

Stichwörter der Autor:innen

ProstacyclinPulmonary arterial hypertensionTreatmentTreprostinil

Substanzen

treprostinilAntihypertensive AgentsEpoprostenol

Autor:innen und Institutionen

  • Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany, satenik.harutyunova@med.uni-heidelberg.de.
  • Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany, satenik.harutyunova@med.uni-heidelberg.de.
  • Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
  • Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Institute of Human Genetics, Laboratory for Molecular Genetic Diagnostics, Heidelberg University, Heidelberg, Germany.
  • Internal Medicine Section, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.

Zitieren

APA

Harutyunova, S., Benjamin, N., Eichstaedt, C., Marra, A. M., Xanthouli, P., Nagel, C., Grünig, E., & Egenlauf, B. (2023). Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension. Respiration. https://doi.org/10.1159/000531169

Vancouver

Harutyunova S, Benjamin N, Eichstaedt C, Marra AM, Xanthouli P, Nagel C, et al. Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension. Respiration. 2023. doi:10.1159/000531169

BibTeX
@article{Harutyunova2023,
  author = {Harutyunova, Satenik and Benjamin, Nicola and Eichstaedt, Christina and Marra, Alberto M and Xanthouli, Panagiota and Nagel, Christian and Grünig, Ekkehard and Egenlauf, Benjamin},
  title = {Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension},
  journal = {Respiration},
  year = {2023},
  doi = {10.1159/000531169}
}
Kostenlos starten →